Quadrant Capital Group’s KalVista Pharmaceuticals KALV Stock Holding History

Quadrant Capital Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.8K	Hold	1,232	–	–	﹤0.01%	1934
2025 Q4	$19.9K	Buy	1,232 +455	+59%	+$6.03K	﹤0.01%	1994
2025 Q3	$9.46K	Buy	+777	New	+$10.7K	﹤0.01%	2180
2025 Q2	–	Sell	-337	Closed	-$3.89K	–	1995
2025 Q1	$3.89K	Buy	+337	New	+$3.44K	﹤0.01%	2405
2024 Q2	–	Sell	-81	Closed	-$961	–	2741
2024 Q1	$961	Buy	+81	New	+$1.08K	﹤0.01%	2591
2022 Q4	–	Sell	-27	Closed	–	–	2796
2022 Q3	$0	Sell	27 -8	-23%	-$112	﹤0.01%	2718
2022 Q2	$0	Hold	35	–	–	﹤0.01%	2632
2022 Q1	$1K	Hold	35	–	–	﹤0.01%	2322
2021 Q4	$0	Hold	35	–	–	﹤0.01%	2605
2021 Q3	$1K	Hold	35	–	–	﹤0.01%	2328
2021 Q2	$1K	Hold	35	–	–	﹤0.01%	2285
2021 Q1	$1K	Hold	35	–	–	﹤0.01%	2235
2020 Q4	$1K	Hold	35	–	–	﹤0.01%	2135
2020 Q3	$0	Buy	+35	New	+$438	﹤0.01%	2239

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's KALV Position: Q1 2026 in Review

Quadrant Capital Group held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 1,232 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Quadrant Capital Group first reported a position in KALV in Q3 2020 and has held it in 14 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Quadrant Capital Group held 1,232 shares of KalVista Pharmaceuticals worth $24.8K as of Q1 2026.
Quadrant Capital Group left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1934 holding.
Quadrant Capital Group first reported a position in KalVista Pharmaceuticals in Q3 2020 and has held it in 14 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.